Amylin Pharmaceuticals, Inc. to Present at the 18th Annual Credit Suisse Healthcare Conference

SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

CONTACT: Financial, Michael York, Senior Director, Investor Relations,
+1-858-458-8602, michael.york@amylin.com, or Media, Anne Erickson, Senior
Director, Corporate Affairs, +1-858-754-4443, anne.erickson@amylin.com,
both of Amylin Pharmaceuticals, Inc.

Web site: http://www.amylin.com/